help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 63, No. 1 246-248
doi:10.1210/jcem-63-1-246
Copyright © 1986 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by NETELENBOS, J. C
Right arrow Articles by HACKENG, W. H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by NETELENBOS, J. C
Right arrow Articles by HACKENG, W. H. L.

Absence of Effect of 24,25-Dihydroxyvitamin D3 in Primary Hyperparathyroidism

J. C NETELENBOS, H. ASSCHEMAN, P. LIPS, W. J. F. VAN DER VIJGH, M. J. M. JONGEN, F. VAN GINKEL and W. H. L. HACKENG

Department of Internal Medicine, Academisch Ziekenhuis Vrije Universiteit Amsterdam, The Netherlands
Bergwegziekenhuis Rotterdam, The Netherlands

Address correspondence and requests for reprints to: Dr. J. C. Netelenbos, Department of Internal Medicine, Academisch Ziekenhuis Vrije Universiteit, P.O. Box 7057,1007 MB, Amsterdam, The Netherlands.

Nineteen patients with primary hyperparathyroidism were treated with 25 µg 24,25-dihydroxyvitamin D3 or placebo daily for 3 months according to double-blind cross-over protocol. Serum immunoreactive PTH, total and ionized calcium, urinary calcium excretion, tubular reabsorption of phosphate/glomerular filtrate, and urinary hydroxyproline excretion did not change significantly. Serum 24,25-dihydroxyvitamin D3 levels increased significantly from 1.4 ± 2.2 (SD) nmol/liter to 38 ± 11 nmol/liter during the treatment period. Serum 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 levels did not change. We conclude that pharmacological doses of 24,25-dihydroxyvitamin D3 have no suppressive effect on parathyroid function in primary hyperparathyroidism.

Received November 15, 1985.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society